Stay updated on Combo Immunotherapies vs Pembrolizumab in NSCLC Clinical Trial
Sign up to get notified when there's something new on the Combo Immunotherapies vs Pembrolizumab in NSCLC Clinical Trial page.

Latest updates to the Combo Immunotherapies vs Pembrolizumab in NSCLC Clinical Trial page
- Check6 days agoChange DetectedThe page revision label was updated from v3.6.1 to v3.6.3, indicating a newer deployment of the page template.SummaryDifference0.0%

- Check13 days agoChange DetectedRevision: v3.6.1 replaces the previous v3.6.0 on the page. This indicates a small update to the page’s revision metadata rather than changes to the study content.SummaryDifference0.0%

- Check20 days agoNo Change Detected
- Check28 days agoChange DetectedThe page gains new guidance sections (How to Read a Study Record, Common Questions, How to Join a Study) and a recruitment note indicating recruitment is closed; the Intervention/Treatment header is standardized, and the revision note updates from v3.5.5 to v3.6.0.SummaryDifference0.3%

- Check35 days agoChange DetectedStudy locations were updated to reflect a new Blacksburg, VA site (ZIP 24060) and the removal of the previous ZIP 24014. This change updates the geographic availability of trial sites.SummaryDifference0.2%

- Check49 days agoChange Detected- The page revision changed from v3.5.3 to v3.5.4, indicating a newer version of the study record.SummaryDifference0.0%

- Check63 days agoChange Detected- New timestamps were added to the Study Record Dates to reflect the most recent maintenance events (QC submission and posting). These entries update the record's activity timeline.SummaryDifference0.2%

Stay in the know with updates to Combo Immunotherapies vs Pembrolizumab in NSCLC Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Combo Immunotherapies vs Pembrolizumab in NSCLC Clinical Trial page.